The estimated Net Worth of Ekaterina Malievskaia is at least $33.7 Milion dollars as of 20 May 2024. Dr Malievskaia owns over 31,207 units of COMPASS Pathways plc stock worth over $26,932,056 and over the last 3 years he sold CMPS stock worth over $6,280,724. In addition, he makes $536,398 as Co-Founder i Chief Innovation Officer & Exec. Director at COMPASS Pathways plc.
Sign up
Dr D CMPS stock SEC Form 4 insiders trading
Dr has made over 12 trades of the COMPASS Pathways plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 31,207 units of CMPS stock worth $246,535 on 20 May 2024.
The largest trade he's ever made was selling 95,016 units of COMPASS Pathways plc stock on 2 January 2024 worth over $843,742. On average, Dr trades about 37,722 units every 47 days since 2022. As of 20 May 2024 he still owns at least 3,931,687 units of COMPASS Pathways plc stock.
You can see the complete history of Dr Malievskaia stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Ekaterina Malievskaia M.D. biography
Dr. Ekaterina Malievskaia M.D. is the Co-Founder, Chief Innovation Officer & Exec. Director at COMPASS Pathways plc.
What is the salary of Dr D?
As the Co-Founder i Chief Innovation Officer & Exec. Director of COMPASS Pathways plc, the total compensation of Dr D at COMPASS Pathways plc is $536,398. There are 1 executives at COMPASS Pathways plc getting paid more, with George Jay Goldsmith having the highest compensation of $722,792.
How old is Dr D?
Dr D is 54, he's been the Co-Founder i Chief Innovation Officer & Exec. Director of COMPASS Pathways plc since . There are 2 older and 1 younger executives at COMPASS Pathways plc. The oldest executive at COMPASS Pathways plc is George Jay Goldsmith, 67, who is the Co-Founder, Chairman & CEO.
What's Dr D's mailing address?
Ekaterina's mailing address filed with the SEC is COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON, X0, W1F 0DQ.
Insiders trading at COMPASS Pathways plc
Over the last 3 years, insiders at COMPASS Pathways plc have traded over $12,645,913 worth of COMPASS Pathways plc stock. The most active insiders traders include George Jay Goldsmith, Ekaterina Malievskaia oraz Gino Santini. On average, COMPASS Pathways plc executives and independent directors trade stock every 32 days with the average trade being worth of $359,563. The most recent stock trade was executed by Ekaterina Malievskaia on 20 May 2024, trading 31,207 units of CMPS stock currently worth $246,535.
What does COMPASS Pathways plc do?
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
What does COMPASS Pathways plc's logo look like?
Complete history of Dr Malievskaia stock trades at COMPASS Pathways plc
COMPASS Pathways plc executives and stock owners
COMPASS Pathways plc executives and other stock owners filed with the SEC include:
-
George Jay Goldsmith,
Co-Founder, Chairman & CEO -
Dr. Ekaterina Malievskaia M.D.,
Co-Founder, Chief Innovation Officer & Exec. Director -
Lars Christian Wilde,
Sr. Advisor -
Dr. Susan C. Stansfield,
Sr. VP of Clinical Operations -
Dr. Greg Ryslik Ph.D.,
Sr. VP of Data Science, Machine Learning & Digital Health Research -
Trevor Mill,
Chief Devel. Officer -
Marco Mohwinckel,
Chief Commercial Officer -
Tracy Cheung,
Chief Communications Officer -
Stephen D. Schultz,
Sr. VP of Investor Relations -
Michael F. Falvey,
Chief Financial Officer -
Daphne Karydas,
Director -
Annalisa Jenkins,
Director -
David Y Norton,
Director -
Matthew A Owens,
General Counsel & CLO -
Guy Goodwin,
Chief Medical Officer -
Robert Mc Quade,
Director -
Thomas Lonngren,
Director -
Wayne Joseph Riley,
Director -
Kabir Nath,
Chief Executive Officer -
Michael Falvey,
Chief Financial Officer -
George Jay Goldsmith,
10% owner -
Ekaterina Malievskaia,
10% owner -
Mary Rose Hughes,
Interim CFO -
Teri Loxam,
Chief Financial Officer -
Gino Santini,
Director